Development and validation of a hybrid immunoaffinity LC–MS/MS assay for quantitation of total antibody (TAb) from an antibody drug conjugate (ADC) PYX-201 in human plasma

•A hybrid immunoaffinity LC-MS/MS assay was fully validated to measure PYX–201 tAb concentrations in human K2EDTA plasma.•This assay validation followed 2018 U.S. FDA guidance and 2022 ICH M10 guidance for industry in bioanalytical method validation.•This is the first bioanalytical assay validation...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of chromatography. B, Analytical technologies in the biomedical and life sciences Analytical technologies in the biomedical and life sciences, 2023-08, Vol.1228, p.123844-123844, Article 123844
Hauptverfasser: Yin, Feng, Adhikari, Diana, Peay, Marlking, Cortes, Diego, Garada, Mohammed, Shane Woolf, M., Ma, Eric, Lebarbenchon, Diane, Mylott, William, Dyszel, Mike, Harriman, Shawn, Pinkas, Jan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 123844
container_issue
container_start_page 123844
container_title Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
container_volume 1228
creator Yin, Feng
Adhikari, Diana
Peay, Marlking
Cortes, Diego
Garada, Mohammed
Shane Woolf, M.
Ma, Eric
Lebarbenchon, Diane
Mylott, William
Dyszel, Mike
Harriman, Shawn
Pinkas, Jan
description •A hybrid immunoaffinity LC-MS/MS assay was fully validated to measure PYX–201 tAb concentrations in human K2EDTA plasma.•This assay validation followed 2018 U.S. FDA guidance and 2022 ICH M10 guidance for industry in bioanalytical method validation.•This is the first bioanalytical assay validation on tAb of the investigational ADC, PYX–201 in human plasma.•This bioanalytical LC-MS/MS assay successfully supported first-in-human (FIH) phase I clinical trial. A hybrid immunoaffinity LC-MS/MS assay was developed and validated for the quantitation of total antibody (TAb) from an antibody drug conjugate (ADC) PYX-201 in human plasma. PYX–201 was proteolyzed using trypsin, and a characteristic peptide fragment PYX-201 P1 with ten amino acids IPPTFGQGTK from the complementarity-determining regions (CDRs) was used as a surrogate for the quantitation of the TAb from PYX-201. Stable isotope labelled (SIL) peptide I(13C6, 15N)PPTFG(13C9, 15N)QGTK was used as the internal standard (IS). We performed chromatographic analysis using a Waters Acquity BEH Phenyl column (2.1 mm x 50 mm, 1.7 µm). Quantification of PYX-201 TAb was carried out on a Sciex triple quadrupole mass spectrometer API 6500 using multiple reaction monitoring (MRM) mode with positive electrospray ionization. To validate PYX–201 TAb, a concentration range of 0.0500 µg/mL to 20.0µg/mL was used, yielding a correlation coefficient (r) of ≥ 0.9947. For intra-assay measurements, the percent relative error (%RE) ranged from -23.2% to 1.0%, with a coefficient of variation (%CV) of ≤14.2%. In terms of inter–assay measurements, the %RE was between -10.5% and -5.7%, with a %CV of ≤12.7%. The average recovery of the analyte was determined to be 81.4%, while the average recovery of the internal standard (IS) was 97.2%. Furthermore, PYX–201 TAb demonstrated stability in human plasma and human whole blood under various tested conditions. This assay has been successfully applied to human sample analysis to support a clinical study.
doi_str_mv 10.1016/j.jchromb.2023.123844
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3153195037</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1570023223002544</els_id><sourcerecordid>3153195037</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-f1716313fbd7575b7679ad11e65f4f1cb1409682833a158f569582377f3a7f233</originalsourceid><addsrcrecordid>eNqFkcFu1DAQhiMEoqXwCCAft4dsPXYcJye02kJB2gqkFqmcLCe2u14l9tZ2VsqNd-A5eKk-CVntUo492frn-z0z_rPsPeA5YCgvNvNNuw6-b-YEEzoHQquieJGdQsVpTnl593K6M47zqUpOsjcxbjAGjjl9nZ1Qznhd4uI0-3Opd7rz2167hKRTaCc7q2Sy3iFvkETrsQlWIdv3g_PSGOtsGtFq-fjr9_XNxfUNkjHKERkf0MMgXbLpyZx8kh3aa41XI5rdLppzZKaZJ-2_rMJwj1rvNsO9TBrNFpfLc_T9511OMCDr0HroJ3zbydjLt9krI7uo3x3Ps-zH50-3yy_56tvV1-Vilbe0rlJugENJgZpGTYuyhpe8lgpAl8wUBtoGClyXFakolcAqw8qaVYRybqjkhlB6ls0O726Dfxh0TKK3sdVdJ532QxQUGIWaYcqfRUnFAApCSjyh7IC2wccYtBHbYHsZRgFY7EMVG3EMVexDFYdQJ9-HY4uh6bV6cv1LcQI-HgA9_cnO6iBia7VrtbJBt0kob59p8RdiYLVq</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2851142260</pqid></control><display><type>article</type><title>Development and validation of a hybrid immunoaffinity LC–MS/MS assay for quantitation of total antibody (TAb) from an antibody drug conjugate (ADC) PYX-201 in human plasma</title><source>Elsevier ScienceDirect Journals</source><creator>Yin, Feng ; Adhikari, Diana ; Peay, Marlking ; Cortes, Diego ; Garada, Mohammed ; Shane Woolf, M. ; Ma, Eric ; Lebarbenchon, Diane ; Mylott, William ; Dyszel, Mike ; Harriman, Shawn ; Pinkas, Jan</creator><creatorcontrib>Yin, Feng ; Adhikari, Diana ; Peay, Marlking ; Cortes, Diego ; Garada, Mohammed ; Shane Woolf, M. ; Ma, Eric ; Lebarbenchon, Diane ; Mylott, William ; Dyszel, Mike ; Harriman, Shawn ; Pinkas, Jan</creatorcontrib><description>•A hybrid immunoaffinity LC-MS/MS assay was fully validated to measure PYX–201 tAb concentrations in human K2EDTA plasma.•This assay validation followed 2018 U.S. FDA guidance and 2022 ICH M10 guidance for industry in bioanalytical method validation.•This is the first bioanalytical assay validation on tAb of the investigational ADC, PYX–201 in human plasma.•This bioanalytical LC-MS/MS assay successfully supported first-in-human (FIH) phase I clinical trial. A hybrid immunoaffinity LC-MS/MS assay was developed and validated for the quantitation of total antibody (TAb) from an antibody drug conjugate (ADC) PYX-201 in human plasma. PYX–201 was proteolyzed using trypsin, and a characteristic peptide fragment PYX-201 P1 with ten amino acids IPPTFGQGTK from the complementarity-determining regions (CDRs) was used as a surrogate for the quantitation of the TAb from PYX-201. Stable isotope labelled (SIL) peptide I(13C6, 15N)PPTFG(13C9, 15N)QGTK was used as the internal standard (IS). We performed chromatographic analysis using a Waters Acquity BEH Phenyl column (2.1 mm x 50 mm, 1.7 µm). Quantification of PYX-201 TAb was carried out on a Sciex triple quadrupole mass spectrometer API 6500 using multiple reaction monitoring (MRM) mode with positive electrospray ionization. To validate PYX–201 TAb, a concentration range of 0.0500 µg/mL to 20.0µg/mL was used, yielding a correlation coefficient (r) of ≥ 0.9947. For intra-assay measurements, the percent relative error (%RE) ranged from -23.2% to 1.0%, with a coefficient of variation (%CV) of ≤14.2%. In terms of inter–assay measurements, the %RE was between -10.5% and -5.7%, with a %CV of ≤12.7%. The average recovery of the analyte was determined to be 81.4%, while the average recovery of the internal standard (IS) was 97.2%. Furthermore, PYX–201 TAb demonstrated stability in human plasma and human whole blood under various tested conditions. This assay has been successfully applied to human sample analysis to support a clinical study.</description><identifier>ISSN: 1570-0232</identifier><identifier>EISSN: 1873-376X</identifier><identifier>DOI: 10.1016/j.jchromb.2023.123844</identifier><identifier>PMID: 37579604</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>ADC ; antibodies ; blood ; chromatography ; drugs ; electrospray ionization mass spectrometry ; extra domain B fibronectin ; human plasma ; humans ; hybrid LBA-LCMS ; hybrids ; oncology ; peptides ; PYX-201 ; spectrometers ; stable isotopes ; total antibody (TAb) ; trypsin ; validation</subject><ispartof>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2023-08, Vol.1228, p.123844-123844, Article 123844</ispartof><rights>2023</rights><rights>Copyright © 2023 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-f1716313fbd7575b7679ad11e65f4f1cb1409682833a158f569582377f3a7f233</citedby><cites>FETCH-LOGICAL-c398t-f1716313fbd7575b7679ad11e65f4f1cb1409682833a158f569582377f3a7f233</cites><orcidid>0000-0003-1655-3542</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1570023223002544$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37579604$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yin, Feng</creatorcontrib><creatorcontrib>Adhikari, Diana</creatorcontrib><creatorcontrib>Peay, Marlking</creatorcontrib><creatorcontrib>Cortes, Diego</creatorcontrib><creatorcontrib>Garada, Mohammed</creatorcontrib><creatorcontrib>Shane Woolf, M.</creatorcontrib><creatorcontrib>Ma, Eric</creatorcontrib><creatorcontrib>Lebarbenchon, Diane</creatorcontrib><creatorcontrib>Mylott, William</creatorcontrib><creatorcontrib>Dyszel, Mike</creatorcontrib><creatorcontrib>Harriman, Shawn</creatorcontrib><creatorcontrib>Pinkas, Jan</creatorcontrib><title>Development and validation of a hybrid immunoaffinity LC–MS/MS assay for quantitation of total antibody (TAb) from an antibody drug conjugate (ADC) PYX-201 in human plasma</title><title>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</title><addtitle>J Chromatogr B Analyt Technol Biomed Life Sci</addtitle><description>•A hybrid immunoaffinity LC-MS/MS assay was fully validated to measure PYX–201 tAb concentrations in human K2EDTA plasma.•This assay validation followed 2018 U.S. FDA guidance and 2022 ICH M10 guidance for industry in bioanalytical method validation.•This is the first bioanalytical assay validation on tAb of the investigational ADC, PYX–201 in human plasma.•This bioanalytical LC-MS/MS assay successfully supported first-in-human (FIH) phase I clinical trial. A hybrid immunoaffinity LC-MS/MS assay was developed and validated for the quantitation of total antibody (TAb) from an antibody drug conjugate (ADC) PYX-201 in human plasma. PYX–201 was proteolyzed using trypsin, and a characteristic peptide fragment PYX-201 P1 with ten amino acids IPPTFGQGTK from the complementarity-determining regions (CDRs) was used as a surrogate for the quantitation of the TAb from PYX-201. Stable isotope labelled (SIL) peptide I(13C6, 15N)PPTFG(13C9, 15N)QGTK was used as the internal standard (IS). We performed chromatographic analysis using a Waters Acquity BEH Phenyl column (2.1 mm x 50 mm, 1.7 µm). Quantification of PYX-201 TAb was carried out on a Sciex triple quadrupole mass spectrometer API 6500 using multiple reaction monitoring (MRM) mode with positive electrospray ionization. To validate PYX–201 TAb, a concentration range of 0.0500 µg/mL to 20.0µg/mL was used, yielding a correlation coefficient (r) of ≥ 0.9947. For intra-assay measurements, the percent relative error (%RE) ranged from -23.2% to 1.0%, with a coefficient of variation (%CV) of ≤14.2%. In terms of inter–assay measurements, the %RE was between -10.5% and -5.7%, with a %CV of ≤12.7%. The average recovery of the analyte was determined to be 81.4%, while the average recovery of the internal standard (IS) was 97.2%. Furthermore, PYX–201 TAb demonstrated stability in human plasma and human whole blood under various tested conditions. This assay has been successfully applied to human sample analysis to support a clinical study.</description><subject>ADC</subject><subject>antibodies</subject><subject>blood</subject><subject>chromatography</subject><subject>drugs</subject><subject>electrospray ionization mass spectrometry</subject><subject>extra domain B fibronectin</subject><subject>human plasma</subject><subject>humans</subject><subject>hybrid LBA-LCMS</subject><subject>hybrids</subject><subject>oncology</subject><subject>peptides</subject><subject>PYX-201</subject><subject>spectrometers</subject><subject>stable isotopes</subject><subject>total antibody (TAb)</subject><subject>trypsin</subject><subject>validation</subject><issn>1570-0232</issn><issn>1873-376X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFkcFu1DAQhiMEoqXwCCAft4dsPXYcJye02kJB2gqkFqmcLCe2u14l9tZ2VsqNd-A5eKk-CVntUo492frn-z0z_rPsPeA5YCgvNvNNuw6-b-YEEzoHQquieJGdQsVpTnl593K6M47zqUpOsjcxbjAGjjl9nZ1Qznhd4uI0-3Opd7rz2167hKRTaCc7q2Sy3iFvkETrsQlWIdv3g_PSGOtsGtFq-fjr9_XNxfUNkjHKERkf0MMgXbLpyZx8kh3aa41XI5rdLppzZKaZJ-2_rMJwj1rvNsO9TBrNFpfLc_T9511OMCDr0HroJ3zbydjLt9krI7uo3x3Ps-zH50-3yy_56tvV1-Vilbe0rlJugENJgZpGTYuyhpe8lgpAl8wUBtoGClyXFakolcAqw8qaVYRybqjkhlB6ls0O726Dfxh0TKK3sdVdJ532QxQUGIWaYcqfRUnFAApCSjyh7IC2wccYtBHbYHsZRgFY7EMVG3EMVexDFYdQJ9-HY4uh6bV6cv1LcQI-HgA9_cnO6iBia7VrtbJBt0kob59p8RdiYLVq</recordid><startdate>20230801</startdate><enddate>20230801</enddate><creator>Yin, Feng</creator><creator>Adhikari, Diana</creator><creator>Peay, Marlking</creator><creator>Cortes, Diego</creator><creator>Garada, Mohammed</creator><creator>Shane Woolf, M.</creator><creator>Ma, Eric</creator><creator>Lebarbenchon, Diane</creator><creator>Mylott, William</creator><creator>Dyszel, Mike</creator><creator>Harriman, Shawn</creator><creator>Pinkas, Jan</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><orcidid>https://orcid.org/0000-0003-1655-3542</orcidid></search><sort><creationdate>20230801</creationdate><title>Development and validation of a hybrid immunoaffinity LC–MS/MS assay for quantitation of total antibody (TAb) from an antibody drug conjugate (ADC) PYX-201 in human plasma</title><author>Yin, Feng ; Adhikari, Diana ; Peay, Marlking ; Cortes, Diego ; Garada, Mohammed ; Shane Woolf, M. ; Ma, Eric ; Lebarbenchon, Diane ; Mylott, William ; Dyszel, Mike ; Harriman, Shawn ; Pinkas, Jan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-f1716313fbd7575b7679ad11e65f4f1cb1409682833a158f569582377f3a7f233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>ADC</topic><topic>antibodies</topic><topic>blood</topic><topic>chromatography</topic><topic>drugs</topic><topic>electrospray ionization mass spectrometry</topic><topic>extra domain B fibronectin</topic><topic>human plasma</topic><topic>humans</topic><topic>hybrid LBA-LCMS</topic><topic>hybrids</topic><topic>oncology</topic><topic>peptides</topic><topic>PYX-201</topic><topic>spectrometers</topic><topic>stable isotopes</topic><topic>total antibody (TAb)</topic><topic>trypsin</topic><topic>validation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yin, Feng</creatorcontrib><creatorcontrib>Adhikari, Diana</creatorcontrib><creatorcontrib>Peay, Marlking</creatorcontrib><creatorcontrib>Cortes, Diego</creatorcontrib><creatorcontrib>Garada, Mohammed</creatorcontrib><creatorcontrib>Shane Woolf, M.</creatorcontrib><creatorcontrib>Ma, Eric</creatorcontrib><creatorcontrib>Lebarbenchon, Diane</creatorcontrib><creatorcontrib>Mylott, William</creatorcontrib><creatorcontrib>Dyszel, Mike</creatorcontrib><creatorcontrib>Harriman, Shawn</creatorcontrib><creatorcontrib>Pinkas, Jan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><jtitle>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yin, Feng</au><au>Adhikari, Diana</au><au>Peay, Marlking</au><au>Cortes, Diego</au><au>Garada, Mohammed</au><au>Shane Woolf, M.</au><au>Ma, Eric</au><au>Lebarbenchon, Diane</au><au>Mylott, William</au><au>Dyszel, Mike</au><au>Harriman, Shawn</au><au>Pinkas, Jan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development and validation of a hybrid immunoaffinity LC–MS/MS assay for quantitation of total antibody (TAb) from an antibody drug conjugate (ADC) PYX-201 in human plasma</atitle><jtitle>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</jtitle><addtitle>J Chromatogr B Analyt Technol Biomed Life Sci</addtitle><date>2023-08-01</date><risdate>2023</risdate><volume>1228</volume><spage>123844</spage><epage>123844</epage><pages>123844-123844</pages><artnum>123844</artnum><issn>1570-0232</issn><eissn>1873-376X</eissn><abstract>•A hybrid immunoaffinity LC-MS/MS assay was fully validated to measure PYX–201 tAb concentrations in human K2EDTA plasma.•This assay validation followed 2018 U.S. FDA guidance and 2022 ICH M10 guidance for industry in bioanalytical method validation.•This is the first bioanalytical assay validation on tAb of the investigational ADC, PYX–201 in human plasma.•This bioanalytical LC-MS/MS assay successfully supported first-in-human (FIH) phase I clinical trial. A hybrid immunoaffinity LC-MS/MS assay was developed and validated for the quantitation of total antibody (TAb) from an antibody drug conjugate (ADC) PYX-201 in human plasma. PYX–201 was proteolyzed using trypsin, and a characteristic peptide fragment PYX-201 P1 with ten amino acids IPPTFGQGTK from the complementarity-determining regions (CDRs) was used as a surrogate for the quantitation of the TAb from PYX-201. Stable isotope labelled (SIL) peptide I(13C6, 15N)PPTFG(13C9, 15N)QGTK was used as the internal standard (IS). We performed chromatographic analysis using a Waters Acquity BEH Phenyl column (2.1 mm x 50 mm, 1.7 µm). Quantification of PYX-201 TAb was carried out on a Sciex triple quadrupole mass spectrometer API 6500 using multiple reaction monitoring (MRM) mode with positive electrospray ionization. To validate PYX–201 TAb, a concentration range of 0.0500 µg/mL to 20.0µg/mL was used, yielding a correlation coefficient (r) of ≥ 0.9947. For intra-assay measurements, the percent relative error (%RE) ranged from -23.2% to 1.0%, with a coefficient of variation (%CV) of ≤14.2%. In terms of inter–assay measurements, the %RE was between -10.5% and -5.7%, with a %CV of ≤12.7%. The average recovery of the analyte was determined to be 81.4%, while the average recovery of the internal standard (IS) was 97.2%. Furthermore, PYX–201 TAb demonstrated stability in human plasma and human whole blood under various tested conditions. This assay has been successfully applied to human sample analysis to support a clinical study.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>37579604</pmid><doi>10.1016/j.jchromb.2023.123844</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-1655-3542</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1570-0232
ispartof Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2023-08, Vol.1228, p.123844-123844, Article 123844
issn 1570-0232
1873-376X
language eng
recordid cdi_proquest_miscellaneous_3153195037
source Elsevier ScienceDirect Journals
subjects ADC
antibodies
blood
chromatography
drugs
electrospray ionization mass spectrometry
extra domain B fibronectin
human plasma
humans
hybrid LBA-LCMS
hybrids
oncology
peptides
PYX-201
spectrometers
stable isotopes
total antibody (TAb)
trypsin
validation
title Development and validation of a hybrid immunoaffinity LC–MS/MS assay for quantitation of total antibody (TAb) from an antibody drug conjugate (ADC) PYX-201 in human plasma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T07%3A39%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20and%20validation%20of%20a%20hybrid%20immunoaffinity%20LC%E2%80%93MS/MS%20assay%20for%20quantitation%20of%20total%20antibody%20(TAb)%20from%20an%20antibody%20drug%20conjugate%20(ADC)%20PYX-201%20in%20human%20plasma&rft.jtitle=Journal%20of%20chromatography.%20B,%20Analytical%20technologies%20in%20the%20biomedical%20and%20life%20sciences&rft.au=Yin,%20Feng&rft.date=2023-08-01&rft.volume=1228&rft.spage=123844&rft.epage=123844&rft.pages=123844-123844&rft.artnum=123844&rft.issn=1570-0232&rft.eissn=1873-376X&rft_id=info:doi/10.1016/j.jchromb.2023.123844&rft_dat=%3Cproquest_cross%3E3153195037%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2851142260&rft_id=info:pmid/37579604&rft_els_id=S1570023223002544&rfr_iscdi=true